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Background: Synchronized diaphragmatic stimulation (SDS) produces localized contractions of the diaphragm
gated to the cardiac cycle to transiently modulate intrathoracic pressures, thereby impacting cardiac function for
heart failure patients with reduced ejection fraction (HFrEF). This study prospectively evaluated the safety and 1year effectiveness of SDS in an expanded ﬁrst-in-patient cohort using multiple implant methods.
Methods: Symptomatic patients with HFrEF despite guideline-directed therapy were enrolled. Patients were
evaluated at 3, 6 and 12 months for adverse events, quality of life (SF-36 QOL), echocardiography and 6-minute
hall walk distance. The SDS system consists of 2 bipolar, active-ﬁxation leads, and an implantable pulse generator.
Results: Nineteen men were enrolled (age 63 [57, 67] years, New York Heart Association class II [53%]/III [47%],
N-terminal pro B-type natriuretic peptide 1779 [886, 2309] pg/mL, left ventricular ejection fraction 27 [23, 33]
%). Three implant techniques (abdominal laparoscopy: sensing and stimulating leads on the inferior diaphragm (n
¼ 15); subxiphoid access for an epicardial sensing lead and abdominal laparoscopy for stimulation on the inferior
diaphragm (n ¼ 2); thoracoscopy to place an epicardial sensing lead and a stimulating lead on the superior
diaphragm (n ¼ 2)) were employed with 100% success. Patients were unaware of diaphragmatic stimulation.
From discharge to 12 months, 6-minute hall walk distance increased (315 [296, 332]m to 340 [319, 384]m; p ¼
0.002), left ventricular end-systolic volume decreased (135 [114, 140]mL to 99 [90, 105]mL; p ¼ 0.04), and SF-36
QOL improved (physical scale 0 [0, 0] to 25 [0, 50], p ¼ 0.004; emotional scale 0 [0, 33] to 67 [33, 67], p ¼
0.001). N-terminal pro B-type natriuretic peptide was lower (1784 [944, 2659]pg/mL vs. 962 [671, 1960]pg/mL;
p ¼ ns) and left ventricular ejection fraction increased (28 [23, 38]% vs. 35 [31, 40]%; p ¼ ns) although neither
reached statistical signiﬁcance. There were no procedure- or SDS-related adverse events.
Conclusions: These data demonstrate that SDS can be delivered using alternative implantation methods without
raising safety concerns and suggest improved outcomes over 1 year of follow-up. Adequately powered randomized trials are now needed to conﬁrm these ﬁndings.
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CRT, cardiac resynchronization therapy; HFrEF, heart failure reduced ejection fraction; SDS, synchronized diaphragmatic stimulation; LVEF, left ventricular ejection fraction; GDMT, guideline-directed medical therapy; ECG,
electrocardiogram; NYHA, New York Heart Association; NT-proBNP, N-terminal pro B-type natriuretic peptide;
LBBB, left bundle branch block.
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Herein we report the 1 year results of the VisONE ﬁrst-in-human heart
failure study with an extended population using alternative implant
techniques on symptomatic HFrEF patients despite guideline-directed
pharmacological therapy.

Introduction
Cardiac resynchronization therapy (CRT) is often an effective treatment for patients in sinus rhythm with heart failure reduced ejection
fraction (HFrEF) and prolonged QRS duration (e.g., LBBB). Despite
guideline-directed medical therapy, the majority of patients with HFrEF
are not candidates for CRT and HF disease progression proceeds with
frequent episodes of decompensation, diminishing quality of life, and
poor prognosis. Alternative device-based therapies for these patients are
desirable, resulting in an increase in the number of HF devices under
development and seeking U.S. Food and Drug Administration approval.1
Synchronized diaphragmatic stimulation (SDS) is a recent HF therapy
which stimulates the diaphragm in a manner imperceptible to the patient2 and at a speciﬁc timepoint in each cardiac cycle, thereby modulating intrathoracic pressure and pericardial restraint to increase
systemic venous return and improve cardiac performance.3–6 Previous
studies used modiﬁed CRT devices with the stimulating lead attached to
the superior left hemisphere of the diaphragm to deliver diaphragmatic
stimulation synchronized to biventricular pacing.3–5 In this manner,
Beeler et al., using a small, randomized cross-over trial design,4 found
that 3 weeks of diaphragmatic stimulation improved dyspnea, functional
capacity, and left ventricular ejection fraction (LVEF), and these improvements may have continued for up to 1 year5 without adverse events
related to diaphragmatic function. A case report6 of a dedicated SDS
system (VisONE) successfully implanted using a minimally invasive
abdominal laparoscopic approach with the stimulating lead attached to
the inferior left hemisphere of the diaphragm demonstrated enhanced
quality of life, exercise tolerance, and cardiac function. Full results of the
VisONE ﬁrst-in-human study (n ¼ 15) have recently been reported.7

Methods
Study Design
This was a prospective, multicenter, multinational, observational
study to investigate the safety and efﬁcacy of delivering SDS to patients
with HFrEF not indicated for CRT who were symptomatic despite
guideline-directed medical therapy (GDMT) as deﬁned by the European
Society of Cardiology/American Heart Association guidelines.8,9 This
included the use of renin-angiotensin-aldosterone system (RAAS) inhibitors, beta-blockers, and mineralocorticoid receptor angtagonists
(MRA). Use of angiotensin receptor-neprilysn inhibitors (ARNI) and
sodium-glucose cotransporter-2 inhibitors (SGLT2) was lower given the
expense and lack of access in Georgia where the study was conducted.
Patient-speciﬁc GDMT was left up to the discretion of the site investigators. There was no independent review committee. The initial
cohort of patients was implanted with the SDS system using a minimally
invasive abdominal laparoscopic approach and the extended population
was implanted using thoracoscopy or subxiphoid mediastinotomy. The
study protocol was approved by the local ethics committee and complied
with the Declaration of Helsinki. All patients provided written informed
consent.
The primary safety outcome was freedom from implant procedure or
therapy-related serious complications or adverse events at 3 and 12

Figure 1. a) Components of the VisONE SDS system. b) Main surgical procedure steps for laparoscopic implant: 1. Midline incision [A1] to place trocar and laparoscope. 2. Incision lateral [A2] to place trocar and introduce leads. 3. Two leads placed on inferior diaphragm [A3]. 4. Create subcutaneous pulse generator pocket
[A4]. Subxiphoid mediastinotomy: 1. Create subxiphoid access to place epicardial sensing lead [B1]. 2. Midline incision [B2] to place trocar and laparoscope. 3.
Incision lateral [B3] to place trocar and introduce stimulation lead [B4]. 4. Create subcutaneous pulse generator pocket [B5]. Thoracoscopy. 1. Incision to place trocar
for left ventricular access [C1]. 2. Incision to place trocar for superior-lateral diaphragm access [C2]. 3. Leads placed on left ventricular epicardium and superior
diaphragm [C3]. 4. Create subcutaneous pulse generator pocket [C4].
Abbreviation: SDS, synchronized diaphragmatic stimulation.
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Echocardiographic Imaging

Table 1
Baseline characteristics of participating patients
Characteristic

All participants
(n ¼ 19)

Age, years
63 [57, 67]
Men
19 (100%)
Medical history
Hypertension
13 (68.4%)
T2DM
7 (36.8%)
IHD
18 (94.7%)
CABG
7 (36.8%)
PTCA
11 (57.9%)
CVA/TIA
1 (5.3%)
Clinical characteristics
NYHA class
II
10 (52.6%)
III
9 (47.4%)
28 [26, 30]
BMI, kg/m2
Heart rate,
74 [63, 87]
bpm
BP systolic,
127 [118, 130]
mm Hg
BP diastolic,
69 [65, 76]
mm Hg
SpO2, %
97 [97, 98]
QRSd, ms
117 [102, 123]
Ejection
27 [23, 33]
fraction, %
6MHW
308 [292, 327]
distance, m
NT-proBNP,
1779 [886, 2309]
pg/mL
119 [108, 133]
Creatinine,
μmol/L
Sodium,
138 [136, 139]
mmol/L
Potassium,
4.4 [4.1, 5.0]
mmol/L
Hemoglobin,
139 [127, 148]
g/dl
eGFR, mL/min
67 [56, 77]
FEV1, liters
2.6 [2.4, 2.8]
FVC, liters
3.2 [3.0, 3.4]

% SDS 80%
group (n ¼ 13)

% SDS <80%
group (n ¼ 6)

66 [61, 69]
13 (100%)

56 [53, 60]*
6 (100%)

10 (76.9%)
5 (38.5%)
12 (92.3%)
5 (38.5%)
6 (46.1%)
1 (7.7%)

3 (50%)
2 (33.3%)
6 (100%)
2 (33.3%)
5 (83.3%)
0 (0%)

9 (69.2%)
4 (30.8%)
28 [26, 29]
74 [60, 87]

1 (16.7%)
5 (83.3%)
28 [28, 31]
78 [69, 95]

127 [117, 129]

124 [118, 133]

70 [66, 78]

68 [63, 70]

97 [97, 98]
113 [103, 123]
30 [23, 34]

97 [97, 98]
118 [100, 125]
25 [23, 33]

308 [295, 335]

307 [293, 311]

1025 [830, 2249]

1859 [911, 2546]

119 [106, 137]

119 [110, 130]

137 [136, 140]

138 [137, 139]

4.3 [4.1, 4.8]

4.9 [4.3, 5.2]

134 [126, 147]

143 [139, 158]

67 [56, 77]
2.6 [2.4, 2.8]
3.1 [3.0, 3.4]

68 [65, 80]
2.6 [2.3, 2.8]
3.4 [3.1, 3.8]

Two-dimensional and Doppler echocardiography was performed by
trained personnel following American Society of Echocardiography
standards in a recumbent left-lateral position using a Philips ClearVue
550 system (Philips, USA). A blinded analysis of the echocardiographic
images from the initial cohort was performed by a core echocardiography
laboratory (University Heart Center, Zurich, Switzerland) while the
extended population of 4 patients was analyzed by an independent,
blinded investigator. LVEF was calculated using the biplane Simpson’s
method and ventricular volumes were measured using the biplane
technique.
SDS System
The SDS system consists of an implantable pulse generator (IPG), 2
sutureless sensing/stimulating leads and a custom laparoscopic tool to
assist with lead placement, Figure 1a. The SDS system senses the
intrinsic QRS complex and then, at a programmed delay, stimulates
the left hemidiaphragm. Adjustable settings for stimulation (pulse
width and amplitude), sensitivity for sensing, and synchronized delay
for stimulation timing gated to the cardiac cycle are programmed
using an external programmer. The IPG also stores the hourly activity
level and the percentage of QRS complexes followed by diaphragmatic stimulation (% SDS, the SDS “dose-response”). The QRS complex must be detected by the IPG but electromyographic noise from
the diaphragmatic muscle during respiration can contaminate the
sensing signal making detection difﬁcult especially in patients with
low-amplitude R-waves. A threshold of 80% SDS was determined
ofﬂine during data analysis for presented results after analysis of
diagnostic data stored within the IPG because it appeared to identify
responders. A group of patients with %SDS 80% (n ¼ 9) in the
original group of 15 patients was identiﬁed by approximately 3
months providing an informal opportunity to assess the dose response
to SDS.
SDS Implantation Procedures

Notes. Values are presented as median and [Q1, Q3] or for categorical variables,
n (%).
6MHW, 6-minute hall walk; BMI, body mass index; BP, blood pressure; CABG,
coronary artery bypass graft; CVA, cerebrovascular accident; eGFR, estimated
glomerular ﬁltration rate; FVC, forced vital capacity; FEV1, forced expiratory
volume, ﬁrst recording; IHD, ischemic heart disease; NYHA, New York Heart
Association; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PTCA,
percutaneous transluminal coronary angioplasty; QRSd, QRS duration; TIA,
transient ischemic attack; T2DM, type 2 diabetes mellitus; SDS, synchronized
diaphragmatic stimulation.
*
p < 0.05.

Placement of SDS Sensing and Stimulation Leads Via Laparoscopy
An initial 1 cm midline incision was made to place the trocar and
laparoscope (Figure 1b, A1), and the abdomen insufﬂated to allow
adequate visualization of the diaphragm and surrounding organs.
Another small incision was made laterally (Figure 1b, A2) to place
another trocar for lead-insertion using a specialized tool to attach the
stimulating lead to the left diaphragm and the sensing lead to the right at
positions (Figure 1b, A3) relative to anatomical markers. A subcutaneous
pocket was created for the IPG (Figure 1b, A4), and the leads tunneled to
connect to it. After device testing the pocket and all open port locations
and incisions were surgically sealed.

months. Assessments made prior to discharge with SDS therapy off and at
follow-up with SDS therapy on at 3, 6, and 12 months included: quality of
life (Short Form [36] Health Survey, SF-36), 6-minute hall walk distance,
New York Heart Association (NYHA) functional class, device-based activity, spirometry, N-terminal pro B-type natriuretic peptide (NTproBNP), and LVEF and left ventricular end-systolic volume by
echocardiography.

Alternative Placement of SDS Sensing Lead Via Subxiphoid Mediastinotomy
As an alternative to sensing the electrocardiogram (ECG) through the
placement of epiphrenic leads on the inferior side of the diaphragm, an
epicardial lead placement via a subxiphoid access was performed prior to
the placement of the diaphragm stimulation lead via laparoscopy. The
surgeon performed a subxiphoid incision to expose the right ventricle
(Figure 1b, B1) and created a pericardial window to attach an activeﬁxation bipolar lead to the myocardium. Once that sensing lead was
placed and tested to conﬁrm adequate sensing, the placement of the
diaphragm stimulation was performed via a laparoscopic access
(Figure 1b, B2 thru B4 similar to the above laparoscopic method). A
subcutaneous pocket was created for the IPG (Figure 1b, B5) and both
leads were tunneled to connect to the IPG. Sensing and stimulating
thresholds were tested and the diaphragmatic capture threshold determined before the pocket and all open port locations and incisions surgically sealed.

Inclusion and Exclusion Criteria
Patients were included if they were in sinus rhythm with <10%
ventricular ectopy, NYHA class II/III, on GDMT with an LVEF 35% and
NT-proBNP >500 pg/mL (>250 pg/mL if on loop diuretics). The exclusion criteria included contraindications to the implant procedure, QRS
duration 140 ms, signiﬁcant pulmonary disease, or an acute coronary
syndrome, cardiac procedure or sustained ventricular arrhythmia within
the previous 3 months.
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Table 2
Change in laboratory and spirometry variables following SDS
Parameter
NT-proBNP, pg/mL
All (n ¼ 19)
% SDS  80%, initial cohort (n ¼
% SDS  80%, all (n ¼ 13)
Creatinine, μmol/L
All (n ¼ 19)
% SDS  80%, initial cohort (n ¼
% SDS  80%, all (n ¼ 13)
Forced expiratory volume (FEV), L
All (n ¼ 19)
% SDS  80%, initial cohort (n ¼
% SDS  80%, all (n ¼ 13)
Forced vital capacity (FVC), L
All (n ¼ 19)
% SDS  80%, initial cohort (n ¼
% SDS  80%, all (n ¼ 13)

Discharge

3-mo follow-up

6-mo follow-up

12-mo follow-up

9)

1784 [944, 2659]
1020 [968, 1898]
1020 [968, 2068]

1190 [884, 2411]*
1024 [871, 1797]*
1024 [871, 1981]*

1061 [898, 1708]
1020 [910, 1400]
975 [760, 1445]*

962 [671, 1960]
962 [736, 1673]
921 [596, 1583]*

9)

121 [108, 129]
115 [107, 133]
115 [107, 133]

115 [101, 127]
115 [107, 118]
115 [95, 118]

110 [94, 117]
102 [97, 117]
106 [96, 116]

116 [100, 122]
114 [95, 116]*
115 [99, 119]

9)

2.6 [2.5, 2.7]
2.8 [2.6, 2.9]
2.8 [2.6, 2.8]

2.5 [2.4, 2.7]
2.9 [2.7, 3.0]*
2.7 [2.5, 2.9]

2.6 [2.5, 2.7]
2.9 [2.8, 2.9]
2.8 [2.7, 2.8]

2.5 [2.4, 2.7]
2.8 [2.5, 3.0]
2.7 [2.4, 2.9]

9)

3.1 [3.0, 3.4]
3.1 [2.9, 3.2]
3.1 [3.0, 3.2]

3.3 [3.0, 3.4]
3.2 [3.0, 3.4]
3.2 [3.0, 3.4]

3.1 [3.0, 3.4]
3.0 [2.9, 3.2]
3.1 [3.0, 3.3]

3.1 [2.9, 3.3]
3.0 [2.9, 3.2]
3.1 [2.9, 3.2]

Notes. Values are median and [quartiles].
One patient with SDS <80% died before the 6-month assessment.
One patient with SDS <80% died before the 12-month assessment.
NT-proBNP, N-terminal pro-B-type natriuretic peptide; SDS, synchronized diaphragmatic stimulation.
*
p-value <0.05 follow-up compared to discharge.

port locations were surgically sealed and a temporary thoracostomy
tube inserted for reinﬂation of the left lung after surgery. A ﬁnal
programmed device test was performed to conﬁrm appropriate
sensing and pacing thresholds before the surgical procedure was
completed.

Alternative Placement of SDS Sensing Lead Via Thoracoscopy
The patient was intubated using a single or dual lumen endotracheal tube to allow for selective ventilation of the right lung and
selective deﬂation of the left lung. Two thoracoscopy ports were
placed in an appropriate intercostal space on the left chest to access
the left ventricular (LV) apex and superior-lateral diaphragm
(Figure 1b, C1). A bipolar active-ﬁxation lead was attached to the
superior left diaphragm, and another was attached to the LV lateral
wall near the apex (Figure 1b, C2 and C3). A subcutaneous pocket
was created for the IPG (Figure 1b, C4), and the leads tunneled for
connection. Sensing and stimulating thresholds were tested and the
diaphragmatic capture threshold determined. The pocket and thoracic

Statistical Analysis
Continuous variables are presented as the median with [interquartile
range] and categorical variables are presented as N (%). Categorical
variables were compared using the Fisher exact test. For comparison of
continuous variables at follow-up to discharge values, a Wilcoxon ranked

Figure 2. Change from discharge to 3, 6, and 12 months postimplant in 6MHW distance, device-based activity, NT-proBNP, QOL parameters (SF-36 role physical and
role emotional), and echocardiographic parameters (LVEF and LVESV) for all patients (n ¼ 19) and patients with synchronized % SDS  of cardiac beats from the
initial cohort (n ¼ 9) and the extended population (n ¼ 13). p-values compared to discharge.
Abbreviations: 6MHW, 6-minute hall walk distance; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; NT-proBNP, N-terminal pro Btype natriuretic peptide; QOL, quality of life.
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Table 3
Change in exercise status, quality of life, activity, and echocardiography following SDS
Parameter
6-min walk test distance, m
All (n ¼ 19)
% SDS  80%, initial cohort (n ¼
% SDS  80%, all (n ¼ 13)
SF-36 Role limitations, physical
All (n ¼ 19)
% SDS  80%, initial cohort (n ¼
% SDS  80%, all (n ¼ 13)
SF-36 Role limitations, emotional
All (n ¼ 19)
% SDS  80%, initial cohort (n ¼
% SDS  80%, all (n ¼ 13)
LV ejection fraction, %
All
% SDS  80%, initial cohort (n ¼
% SDS  80%, all (n ¼ 13)
LV end-systolic volume, ml
All (n ¼ 19)
% SDS  80%, initial cohort (n ¼
% SDS  80%, all (n ¼ 13)
LV end-diastolic volume, mL
All (n ¼ 19)
% SDS  80%, initial cohort (n ¼
% SDS  80%, all (n ¼ 13)
Device-based activity, au
All (n ¼ 19)
% SDS  80%, initial cohort (n ¼
% SDS  80%, all (n ¼ 13)

Discharge

3-mo follow-up

6-mo follow-up

12-mo follow-up

9)

315 [296, 332]
315 [292, 318]
308 [295, 335]

333 [303, 350]*
336 [319, 349]*
336 [296, 351]*

342 [322, 357]*
347 [329, 357]*
348 [327, 365]*

340 [319, 384]*
346 [328, 385]*
368 [334, 386]*

9)

0 [0, 0]
0 [0, 0]
0 [0, 0]

25 [0, 25]
0 [0, 25]
25 [0, 25]

50 [0, 50]*
50 [25, 50]*
50 [44, 50]*

25 [0, 50]*
25 [0, 50]*
25 [12, 50]

9)

0 [0, 33]
0 [0, 0]
0 [0, 0]

33 [0, 67]*
67 [0, 67]*
67 [ 33, 67]*

67 [33, 67]*
67 [33, 67]*
67 [33, 67]*

67 [33. 67]*
33 [33, 67]*
67 [33, 67]*

9)

28 [23, 38]
28 [23, 38]
28 [23, 37]

31 [21, 39]
39 [34, 43]
38 [25, 40]

39 [27, 44]
42 [39, 51]
41 [38, 46]

35 [31, 40]
34 [34, 38]*
35 [34, 41]*

9)

135 [114, 140]
136 [125, 155]
130 [114, 138]

123 [100, 169]
102 [83, 161]
102 [92, 142]

110 [94, 139]*
115 [72, 133]
104 [83, 128]*

99 [90, 105]*
98 [90, 105]*
99 [91, 105]*

9)

180 [175, 221]
183 [176, 250]
180 [175, 194]

180 [158, 241]
180 [154, 231]
171 [154, 196]

188 [137, 237]
187 [136, 254]
174 [135, 212]

165 [136, 183]*
150 [136, 168]*
165 [137, 169]

9)

63 [41, 96]
84 [51, 119]
55 [40, 109]

98 [78. 131]*
110 [98, 145]
109 [76, 143]*

115 [90, 140]*
119 [102, 136]
107 [80, 139]

152 [128, 161]*
151 [127, 163]
154 [128, 163]*

Notes. Values are median and [quartiles].
One patient with SDS <80% died before the 6-month assessment.
One patient with SDS <80% and one patient with SDS  80% died before the 12-month assessment.
LV, left ventricular; SDS, synchronized diaphragmatic stimulation.
*
p-value < 0.05 follow-up compared to discharge.

respectively. The average procedure time for the laparoscopic implant
was 73 minutes. Two patients received an epicardial SDS sensing lead via
subxiphoid incision. Two patients were implanted with the epicardial
sensing lead via thoracoscopy and the stimulating lead on the superior
surface of the left diaphragm. Implantation resulted in no device or
procedure-related adverse events independent of the implant procedure
method. Minimum stimulation energy to capture the diaphragm was 2.5
[2.0, 3.0] V at pulse widths of 0.4 [0.4, 0.4] ms. The diaphragmatic
stimulation capture threshold was identiﬁed by palpation of the
abdomen while adjusting the stimulation energy. Prior to discharge, the
stimulation energy (voltage and/or pulse-width) was increased until the
patient became aware of the stimulus. The IPG was set to deliver a
stimulus well below this threshold and all patients were discharged with
SDS therapy on at an imperceptible stimulation output.

signed test for paired values was performed which excluded missing data,
in particular from patients who died over the progression of the study. A
two-sided p-value <0.05 was used to indicate statistical signiﬁcance.
Statistical analyses were performed using R, version 3.4.1 (2017-06-30
for Windows), MedCalc Statistical Software, version 20.113 (MedCalc
Software Ltd., Ostend, Belgium) and Excel for Microsoft 365, version
16.0 (Microsoft Corporation, Washington, USA).
Results
Baseline Demographics and Medications
Twenty-three symptomatic HF patients were invited to participate,
and 19 men were enrolled in this study. All patients were in sinus rhythm
and all but one (95%) had ischemic heart disease. Use of GDMT was high
with all patients on diuretics and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and 11 patients on beta-blockers.
Few medication changes occurred: one patient had bisoprolol 2.5 mg/
d discontinued at 6 months, another discontinued amlodipine 10 mg/d at
3 months, one patient had carvedilol changed from 6.25 to 12.5 mg twice
daily prior to the 12-month follow-up, one patient had Concor at 2.5 mg
once daily changed to Coraxan 5 mg twice daily at 3 months, and one
patient had ramipril 10 mg once daily decreased to 5 mg once daily prior
to the 12-month follow-up. The median age was 63 [57, 67] years, LVEF
was 27 [23, 33] %, QRS duration was 117 [102, 123] ms, 53% were
NYHA Class II and the others NYHA Class III, and median plasma NTproBNP was 1779 [886, 2309] pg/mL (Table 1).

Follow-Up
Throughout the study, lead impedances were monitored, revealing a
reduction within a few hours after implantation and no signiﬁcant
changes during follow-up. At implant, lead impedance was 1458 [1419,
1739] Ω, at discharge 528 [476, 598] Ω, at 6 months 499 [420, 583] Ω,
and 451 [374, 482] Ω at 12 months. Capture and symptomatic thresholds
were determined at each follow-up. No signiﬁcant adjustments were
necessary. Programmed stimulation voltages at discharge were 3.0 [2.5,
4.5] V, at 3 months 2.5 [1.8, 3.5] V, at 6 months 2.5 [1.8, 3.5] V, and 2.5
[1.8, 4.3] V at 12 months. Interrogation of the IPG found that 13 patients
had 80% SDS (9 from the initial laparoscopic cohort and all 4 alternative implant methods) and 6 had <80% SDS.

Implant Procedure
Safety and Adverse Events
Fifteen patients were implanted with the VisONE system using an
abdominal laparoscopic approach with the sensing and stimulating leads
afﬁxed to the right and left inferior diaphragmatic hemispheres,

There was one serious adverse event (pneumothorax) due to central
line placement, 3 mild adverse events (superﬁcial wound infection,
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Figure 3. Illustration for synchronized diaphragmatic stimulation for heart failure.
Abbreviations: GDMT, guideline-directed medical therapy; HF, heart failure; LV EF, left ventricular ejection fraction; LV ESV, left ventricular end-systolic volume; SF36, Short Form (36) Health Survey.

(Figure 2 and Table 3). Quality of life, as assessed by the SF-36 questionnaire, also improved both for physical (discharge 0 [0, 0] vs. 6
months 50 [0, 50], p < 0.001; 12 months 25 [0, 50] au, p ¼ 0.004) and
emotional components (discharge 0 [0, 33] vs. 6 months 67 [33, 67], p ¼
0.004; 12 months 67 [33, 67] au, p ¼ 0.001) with the effect greater when
SDS was 80%. Daytime device-based activity increased between 3 and
12 months, with values being higher, as expected, than activity recorded
during the 3 days after discharge (Table 3). During 12 months of followup, LV end-systolic volume fell from 135 [114, 140] mL to 99 [90, 105]
mL (p ¼ 0.04) with greater decrease in patients with SDS 80%. LV enddiastolic volume decreased over 12 months (discharge 180 [175, 221] vs.
12 months 165 [136, 183] mL, p ¼ 0.006). A trend to increasing LVEF in
the overall cohort (28 [23, 38] % to 35 [31, 40] %, p ¼ 0.08) was signiﬁcant for those with SDS 80% (28 [23, 37] % vs. 35 [34, 41] %, p ¼
0.008).

transient second-degree AV block, worsening diabetic angiopathy of the
right foot), 2 moderate adverse events (sprained ankle, decompensation
of HF), and 3 severe adverse events (cholecystectomy due to cholelithiasis, acute decompensation of HF, amputation of the right lower leg due
to diabetic angiopathy) during the study. One patient with undisclosed
pre-enrollment and ongoing pulmonary effusions, constituting a protocol
violation, was considered ineligible for the safety analysis. This patient
(SDS <80%) died just prior to his 6-month follow-up from HF. Another
patient (SDS <80%) died 11 months into the study due to an infection
unrelated to SDS while hospitalized for nephrolithotomy. A third patient
(SDS 80%) died suddenly prior to his 12-month follow-up witnessed by
his wife and without new symptoms (etiology unclear; no autopsy performed). Other than the superﬁcial wound infection, no adverse events
related to the SDS procedure, device or leads were reported during the
12-month study period. No patient complained of symptoms due to
diaphragmatic stimulation.

Discussion

Laboratory Data and Spirometry Results

A previous report7 of the initial cohort of the VisONE ﬁrst-in-human
study demonstrated that SDS can be successfully deployed through the
placement of epiphrenic sensing and stimulation leads via abdominal
laparoscopy as a minimally invasive surgical technique that allows for
outpatient implantation. There can be circumstances where an alternative access for the placement of SDS leads is preferred. The purpose of this
extended study was to demonstrate the safety and feasibility of alternate
surgical techniques, namely a subxiphoid mediastinotomy and/or thoracoscopy to place the SDS leads.
We report the feasibility of both minimally invasive abdominal
laparoscopic and alternative implant procedures with a low rate of
complications. SDS implant via any approach can be an outpatient

There were no signiﬁcant changes in forced expiratory volumes,
forced vital capacity, or serum creatinine over 12 months. Plasma concentrations of NT-proBNP were not signiﬁcantly different over 1 year
(discharge 1784 [944, 2659] vs. 12 months 962 [671, 1960] pg/ml, p ¼
ns), although there was a trend for lower values (Table 2).
Effect of SDS on Functional Status, Exercise Capacity and Quality of Life
Six-minute hall walk distance increased from discharge to follow-up
at 12 months (discharge 315 [296, 332] vs. 12 months 340 [319, 384]
m, p ¼ 0.002) with slightly greater improvements when SDS was 80%
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The total number of patients implanted with alternative methods was
limited. There was no control group for comparison. The echocardiography analysis for the patients with alternative lead placements was not
performed by the same group as the initial cohort. There was no evaluation of right ventricular function or diaphragm properties other than
spirometry. Values at discharge were used for comparison.
In conclusion, SDS appears to have a reasonable safety proﬁle with
options for the implantation procedure and delivering asymptomatic and
long-term SDS. Larger randomized clinical trials of SDS are warranted
and soon to be performed in an upcoming randomized controlled study.

procedure while the abdominal laparoscopic procedure has the additional beneﬁt of being extra-cardiac in nature and not occupying space in
the thoracic cavity where other devices might be located. However, in
cases where the abdominal laparoscopic approach is not deemed optimal
other surgical access as reported here is possible. Although limited in the
number of patients, it appears that SDS stimulation can be successfully
delivered over 12 months from both the inferior and superior surfaces of
the diaphragm. SDS was delivered without causing symptoms from diaphragmatic stimulation similar to previous results2–4 and there were no
therapy-related adverse events.
Our results conﬁrm those of previous studies using modiﬁed CRT
devices either in a temporary application of stimulation or longer use of
diaphragmatic stimulation therapy. Roos et al.,3 studied 35 patients who
during bypass surgery had a temporary stimulation lead attached to the
superior diaphragm and found all patients could be stimulated without
symptoms with improvements to an acoustic cardiography parameter
acting as a marker for systolic function. Beeler et al.,4 using a cross-over
trial design (3-week treatment periods) and a modiﬁed CRT device on
chronic HFrEF patients, found that SDS improved NYHA class, dyspnea,
exercise capacity, and LVEF when SDS was optimized within the cardiac
cycle. Continued SDS therapy for a year on these patients,5 suggested that
stimulation thresholds were stable without reported patient symptoms
from diaphragmatic stimulation.
The SDS therapy dose response (%SDS) is deﬁned as the number of
cardiac complexes appropriately sensed so that diaphragmatic stimulation
can be effectively delivered. It appears that patients who received more
SDS did better on measures of exercise tolerance, quality of life, and
functional cardiac parameters. The 80% SDS dose threshold was chosen,
not prespeciﬁed, for the results we present after analysis of diagnostic data
stored within the IPG because it appeared to identify responders. SDS
stimulation is imperceptible to the patient and the % SDS dose was
determined ofﬂine during data analysis, therefore both the patient and
investigators were blinded to the dose delivered. The ﬁrst-generation
device sensing software was not always successful in identifying QRS
complexes due to interference from diaphragmatic electromyographic
activity especially in the presence of low amplitude R waves in patients
with a sensing lead on the diaphragm, which reduced the % SDS for some
patients. Patients with an epicardial sensing lead had %SDS close to
100%. The ECG detection ﬁlter has been optimized for future studies
including an upcoming randomized controlled trial using data collected
by the IPG and will be used to enhance the next generation VisONE system. Future studies should also prespecify SDS thresholds for investigation
of treatment response. We consider it reasonable to believe that successful
delivery of SDS therapy might be associated with better outcomes, but we
also admit that this could reﬂect conﬁrmation bias in the post hoc analysis
particularly for the patients with diaphragmatic sensing leads.
The mechanisms of action of SDS are not fully understood but we can
propose several possibilities. Diaphragmatic movement during inspiration
increases systemic venous return by reducing intrathoracic and increasing
intra-abdominal pressures. Right atrial and right ventricular volume increase while left atrial and LV volume decrease during inspiration. Pericardial restraint may also be reduced.10 SDS produced biphasic changes in
intrathoracic pressure as shown in Figure 3 with data acquired from
continuous ECG and intrathoracic pressure recordings in a porcine model.11
Two research groups, Pinsky et al. and Peters et al., completed a series of
canine and porcine model to determine the impact of transient changes of
intrathoracic pressure relative to the cardiac cycle.12–15 Their ﬁndings
suggest that short transient increased or decreased in intrathoracic pressure
alters both cardiac and large vessel pressures and ﬂows including LV stroke
volume. Pinsky et al. found that increased intrathoracic pressure changes
from high-frequency jet ventilation during systole improved cardiac performance13,14 due to changes in LV afterload and impedance and in venous
return.
The limitations of this study include a small sample size with limited
diversity, in particular with respect to sex and underlying HF etiology.
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